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Deposition of hepatitis B e antigen in membranous glomerulonephri.
tis: Identification by F(ab')2 fragments of monoclonal antibody. The
pathogenic ability of hepatitis B e antigen (HBeAg) to induce membra-
nous glomerulonephritis was evaluated by the most specific method
presently available. Monoclonal antibody was raised against HBeAg,
and F(ab')2 fragments were obtained and labeled with fluorescence. By
this reagent, 10 out of 16 patients with membranous glomerulonephri-
tis with hepatitis B surface antigen in the serum revealed granular
deposition of HBeAg along glomerular capillary walls. Among the cas-
es with glomerular HBeAg deposits, nine had detectable HBeAg in the
serum and one had antibody to HBeAg (anti-HBe). The specificity of
HBeAg staining was ascertained by blocking and inhibition tests, and
the fluoresceinated anti-HBe F(ab')2 reagent did not stain the glomer-
ular immune deposits in the patients with membranous glomerulone-
phritis who did not carry hepatitis B virus (HBV). None of the studied
patients showed deposition of hepatitis B surface or core antigens in
the glomerulus. On the basis of these results, immune complexes in-
volving HBeAg may induce membranous glomerulonephritis in per-
sons who carry HBV.
Dépôt d'antigene e de l'hépatite B au cours des glomerulonephrites
extramembraneuses: identification par fragments F (ab')2 d'un anticorps
monoclonal. La capacité pathogénique pour l'antigène e de l'hépatite
B (HBeAg) d'induire une glomérulonéphrite extramembraneuse a été
évaluée par la méthode la plus spécifique actuellement disponible. Un
anticorps monoclonal a été produit contre HBeAg, et les fragments F
(ab')2 ont éte obtenus et marques par fluorescence. Avec ce réactif, 10
de 16 malades avec glomérulonéphrite extramembraneuse avec
presence d l'antigene de surface de l'hépatite B dans le serum ont
révélé des dépôts granulaires d'HBeAg le long des parois capillaires
glomerulaires. Parmi ces cas avec dépôts glomerulaires d'HBeAg, neuf
avaient de l'HBeAg detectable dans le serum et un avait un anticorps
contre HBeAg (anti-HBe), La spécifite de la coloration de I'HBeAg a
eté vérifiée par des tests de blocage et d'inhibition, et le rdactif fluo-
rescent anti-HBeF(ab')2 ne colorait pas les dépôts immuns
glomerulaires dans les malades avec glomerulonephrite extramembra-
neuse non porteurs du virus de l'hépatite B (HBV). Aucun des malades
dtudids na présenté de dCpAt d'antigénes de surface ou du core de
l'hépatite B dans le glomerule. Sur la base de ces résultats, les im-
muns complexes comportant de l'HBeAg pourraient induire une
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glomérulonephrite extramembraneuse chez les personnes porteuses de
I'HBV.
Hepatitis B virus (HBV) induces a spectrum of hepatic dis-
eases in the host [1]. In addition, persons with persistent HBV
infection may present with extra-hepatic diseases including re-
nal injuries, such as membranous [2], membranoproliferative
[3], and mesangioproliferative glomerulonephritis [4]. Among a
variety of nephritides associated with HBV infection, membra-
nous glomerulonephritis (MN), first reported by Combes et a!
in 1971 [2], is by far the commonest and many cases have been
described up to the present.
Three distinct antigens are presently recognized in associa-
tion with HBV infection. They are hepatitis B surface antigen
(HBsAg), hepatitis B core antigen (HBcAg), and hepatitis B e
antigen (HBeAg). Which of these antigens is responsible for
MN, however, is not established as yet [51. To make the mat-
ter more difficult, a serious question has been addressed by
Maggiore et al [6] concerning the specificity of fluorescent
staining for HBV-associated antigens in glomerular immune
deposits.
Utilizing fluorescent antibody technique, we have reported
finding HBeAg in glomerular immune deposits in patients with
MN who carried HBV [7] and related the disease activity with
HBeAg in their circulation [8]. For the purpose of staining
glomerular HBeAg deposits more specifically, we now intro-
duce fluoresceinated F(ab')2 fragments of monoclonal antibody
raised against HBeAg.
Methods
Patients. Patients who carried HBsAg and presented with
pathological proteinuria received percutaneous renal biopsy.
Sixteen of them revealed immunohistological evidence of MN,
and they were studied for the deposition of HBV-associated
antigens in the glomerulus, as well as for HBV-related mark-
ers in the serum. In addition, 15 patients with MN (eight with
idiopathic MN and seven with systemic lupus erythematosus)
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Table 1. HBV-related markers in the circulation and glomerulus of patients with membranous glomerulonephritis carrying HBsAg
Patient
no.
Age
and
sex
Circulation Deposition in the glomerulus
HBsAga
titer
HBeAgb Anti-HBc
titer
HBsAg HBeAg HBcAg IgG
immunofluorescent stainingd
1gM C3
1 3F 10 + 14 — + — + — —
2 4F 11 — 12 — — — + + —
3 SM 12 + 15 — + — + — +
4 6M 9 + 12 — + — + + +
5 8F 13 + 11 — + — + — —
6 8F 7 — 13 — — — + — —
7 8M 11 -- 15 — + — + + —
8 11F 11 — 14 — — — + — —
9 12F 8 — 12 — — — + — —
10 12 M 12 + 15 — + — + + +
11 14M 10 + 11 — + — + + +
12 14 M 13 — 12 — + — + — —
13 26M 14 + 14 — + — + + +
14 32 M 11 — 15 — — — + — —
15 40M 7 — 12 — — — + — —
16 48M 12 + 16 — + — + — +
Abbreviations: HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBcAg, hepatitis B core antigen;
anti-HBc, antibody against HBcAg.
a HB5Ag was determined by reversed passive hemagglutination [9], and the titer was expressed by the highest dilution of the serum (2N) that
showed positive reaction.
b HBeAg was determined by radioimmunoassay [11]. The sera negative for HBeAg were positive for the antibody against HBeAg.
Anti-HBc was tested by immune adherence hemagglutination [10], and the results were expressed in a similar manner as for HBsAg.
d HBsAg and HBcAg were stained by horse antibody and human antibody, respectively, by the method previously described [12]. HBeAg
was stained by (F(ab')2 fragments of monoclonal antibody labeled with FITC (see Methods).
who were seronegative for HBsAg were studied as control
subjects.
Serological tests. HBsAg and the corresponding antibody
(anti-HBs) were determined by reversed passive hemaggluti-
nation [9] and antibody to HBcAg (anti-HBc) by immune ad-
herence hemagglutination [10]. HBeAg and corresponding anti-
body (anti-HBe) were determined by radioimmunoassay [11].
Morphologic and immunopathological studies. For light
microscopic observations, renal tissue samples were fixed in
10% neutral formalin, embedded in paraffin, cut at 2-sm thick-
ness, and stained with periodic acid-Shiff. A portion of renal
tissue was snap-frozen in n-hexane cooled in a dry-ice/acetone
bath, and cut at 4-sm thickness in a cryostat. Frozen kidney
sections were stained for IgG, 1gM, and C3 by respective anti-
bodies labeled with fluorescein isothiocyanate (FITC) that
were obtained from a commercial source (Behringswerke,
Marburg-Lahn, West Germany).
Fluorescent staining for HBV-associated antigens. HBsAg
and HBcAg were stained with FITC-labeled horse anti-HBs
and human anti-HBc, respectively, after the method described
previously [121.
Monoclonal anti-HBe was produced by the method de-
scribed elsewhere [13]. Briefly, BALB/c mice were immunized
with HBeAg purified from plasma containing ilBeAg along
with a high titer of HBsAg [14]. Immune spleen cells were har-
vested and fused with mouse myeloma (NS-1) cells. Hybridi-
zation, subsequent culture and cloning were performed in ac-
cordance with the method of Di and Herzenberg [15]. Clones
producing anti-HBe were grown in the peritoneal cavity of
mice made ascitic by the intraperitoneal injection with
2,6,10,l4-tetramethylpentadecane. Ascites fluid was harvested
and y-globulin fraction was precipitated with 1.33 M
(NH4)2S04.
Monoclonal anti-HBe was digested with pepsin, and F(ab')2
fragments were obtained. They were conjugated with FITC at
an F/P ratio of 1.0 and used as a reagent to stain HBeAg
specifically.
Specificity for the staining of HBeAg was further ascer-
tained by absorption and blocking tests. FITC-labeled anti-
HBe (Fab')2 fragments with a staining titer of 1:64 was diluted
twofold in buffer and mixed with an equal volume of a purified
HBeAg preparation (hemagglutination titer 2' '[141). After in-
cubation at 37°C for 1 hr, it was centrifuged at 3,000 rpm for
15 mm, and the supernatant was tested for the ability to stain
immune deposits in the kidney. For blocking tests, kidney sec-
tions containing HBeAg deposits were first incubated at 37°C
for 30 mm with unlabeled anti-HBe F(ab')2 fragments. Sec-
tions were then washed and stained with the labeled anti-HBe
F(ab')2 fragments.
Results
Table I summarizes HBV-related serum markers and im-
munopathological findings in 16 patients with MN who carried
HBsAg. All were positive for HBsAg and anti-HBc with high
titers, thereby indicating that they were persistent carriers of
HBY. HBeAg was found in nine and the other seven had anti-
HBe in the serum.
The pathology in glomeruli from all patients was compatible
with MN with diffuse granular deposition of IgG along glomer-
ular capillary walls and minimal mesangial cell proliferation.
The deposition of HBeAg along glomerular capillary walls was
found in ten of them. Among the ten with glomerular HBeAg
deposits, nine had HBeAg in the serum, but the remaining one
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Fig. l.A frozen kidney section of patient 16 stained with FITC-labeled
F(ab)2 fragments of monoclonal antibody against hepatitis B e anti-
gen. Note diffuse granular staining of HBeAg along glomerular capil-
lary walls. In nearby sections, the deposition of IgG and C3 was ob-
served in a similar pattern. (x 500)
was seropositive for anti-HBe. Deposition of HBsAg or
HBcAg was observed in none of the cases.
Figure 1 shows the granular deposition of HBeAg along
glomerular capillary walls of patient 16 that were stained with
FITC-labeled monoclonal anti-HBe F(ab')2 fragments. Similar
staining was observed in the other nine patients.
The specificity of HBeAg staining was ascertained by block-
ing and inhibition tests. Furthermore, the fluorescent anti-HBe
F(ab')2 fragments did not stain immune deposits in 15 patients
with MN (eight idiopathic MN and seven with lupus nephritis)
who did not carry HBsAg.
Discussion
In areas of high endemicity of HBV such as Asia, MN is
closely associated with HBV infection. Takekoshi et al [16]
studied the pathology in the kidney of 163 children with ab-
normal proteinuria and/or hematuria, and identified 11 patients
with MN all of whom turned out to be carriers of HBV. Their
observation was confirmed in Taiwan by a recent study of Hsu
et al [171. They diagnosed MN in 14 out of 63 children with pri-
mary glomerular diseases. Among the 14 MN patients in their
series, all 13 tested were positive for HBsAg in the serum. De-
spite these undisputable correlations between HBV infection
and MN, the causal relation is not yet clear [5]; it still remains
to be seen which of the three antigens associated with HBV in-
fection may induce MN.
HBsAg was proposed as the etiological antigen by Combes
et al in 1971 [2] when HBsAg was practically the sole HBV-
associated antigen known. In later studies, HBsAg was stained
by direct and indirect fluorescent antibody techniques in a
number of patients with MN who were carriers of HBV [5].
Slusarczyk et al [18] found the deposition of HBcAg in 14 out
of 23 patients with HBV-associated MN, but their observation
was not reproduced by any other groups. Takekoshi et al [7]
reported finding HBeAg, but not HBsAg or HBcAg, along
glomerular capillary walls in two children with MN. Their find-
ings were extended to an additional four children reported sub-
sequently [81. Collins et al [19] also described a 29-year-old
man in whom granular deposition of HBeAg was observed
along glomerular capillary walls.
HBeAg was added to the scene by Magnius and Espmark in
1972 [20], 7 years after the discovery of HBsAg and 1 year af-
ter the introduction of HBcAg, as the third antigen associated
with HBV infection. In actuality, HBeAg represents the anti-
genic determinant(s) on the nucleoprotein of HBV with a mo-
lecular size of 19,000 daltons (P19) [211. P19 also bears the anti-
genic determinant of HBcAg [21]; it loses the portion bearing
HBcAg to make a polypeptide of 15,500 daltons (P15.5) [22].
In the circulation, P15.5 binds with plasma proteins to make
free small HBeAg as well as IgG-bound large HBeAg [23]. In
the circulation of a chimpanzee acutely infected with HBV,
small HBeAg appeared first and gradually shifted to IgG-bound
large HBeAg [241. Finally, even the IgG-bound HBeAg dis-
appeared to be taken over by anti-HBe. The shift from small
HBeAg to IgG-bound large form takes place in the circulation
of persons persistently infected with HBV, too [24]. This se-
ries of events strongly implies that the IgG-bound large HBeAg
would represent the immune complex involving anti-HBe.
Persons infected with HBV either temporarily or persist-
ently seroconvert from HBeAg to anti-HBe [25, 26]. Such sero-
conversion has important virologic and clinical bearings [27].
There is evidence to support that the presence of HBeAg, most
likely its IgG-bound form, is required to maintain the pathol-
ogy of MN. Ito et al [81 compared the presence of HBeAg or
anti-HBe in the circulation with clinicopathological activities of
MN. They detected the deposition of HBeAg, as well as elec-
tron-dense materials, in the glomerular basement membrane of
four children with proteinuria who were positive for HBeAg in
the serum. In contrast, HBeAg deposits were not detectable,
but electron-lucent areas were found in the glomerulus of two
children who once had an active disease but remitted clinically
as they seroconverted for anti-HBe.
We tried to re-evaluate the pathogenic ability of HBeAg in
inducing HBV-associated MN. Our attempt was instigated by
the recent study of Maggiore et al [6] who cast a serious doubt
on the staining of HBV-associated antigens in glomerular im-
mune deposits of persons who carry HBV. They detected cry-
oglobulin that contained antiglobulin activity of 1gM class in
patients who carried HBV. Glomerular immune deposits of
these patients, especially those containing 1gM, were stained
by fluoresceinated anti-HBs, but the staining was nonspecific
since it was abolished when FITC-labeled anti-EBs F(ab')2
fragments were used in place of the fluoresceinated whole anti-
HBs.
We obtained monoclonal anti-HBe, prepared its F(ab')2 frag-
ments, and then labeled them with fluorescence. The FITC-
anti-HBe F(ab')2 may represent the most specific reagent for
staining HBeAg presently available. Utilizing this reagent, im-
mune deposits in the glomerulus from 10 out of 16 patients with
MN carrying HBsAg were stained for HBeAg. Immune depos-
its in none of these patients were stained for HBsAg or
HBcAg. These observations have made it clear that HBeAg is
actually present in the glomerular deposits of patients with MN
who carry HBV.
Among ten patients with glomerular HBeAg deposits, nine
were positive for HBeAg in the serum, but the remaining one
(patient 12) had anti-HBe. The patient with anti-HBe may have
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been on the process of recovery after having seroconverted for
anti-HBe. Frequent urinalyses for an expected early disappear-
ance of proteinuria would be necessary to establish this.
There were six patients in our series who did not show the
deposition of HBeAg in the glomerulus at the time of study.
Since all of them had anti-HBe in the serum, it could be as-
sumed that the seroconversion had been taken place in the near
past with the loss of HBeAg deposits; they might have been
suffering from a residual disease. Alternatively, MN in these
patients could have been induced by HBV-associated
antigen(s) other than HBsAg, HBcAg, or HBeAg. The DNA of
HBV is 3,182 nucleotides long [28], and not all of its sequence
has been correlated with known products of the virus, such as
HBsAg, HBcAg, and HBeAg. There is an ample capacity left
for coding yet unidentified antigens, some of which may well
be nephritogenic.
Reprint requests to Dr. M. Mayumi, Immunology Division, Jichi
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